Colistimethate sodium for injection — Competitive Intelligence Brief

Colistimethate sodium for injection (Colistimethate sodium for injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polymyxin antibiotic. Area: Infectious Disease.

phase 3 Polymyxin antibiotic Bacterial lipopolysaccharide and phospholipid membranes Infectious Disease Small molecule

Target snapshot

Colistimethate sodium for injection (Colistimethate sodium for injection) — Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Colistimethate sodium is a prodrug of colistin that disrupts bacterial cell membranes by binding to lipopolysaccharides and phospholipids, leading to cell lysis and death.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Colistimethate sodium for injection TARGET	Colistimethate sodium for injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Polymyxin antibiotic	Bacterial lipopolysaccharide and phospholipid membranes
Polymyxin e	Polymyxin e	Mahmoud I Mostafa	marketed	Polymyxin antibiotic	Bacterial lipopolysaccharides and phospholipids
Standard Dose Colistin	Standard Dose Colistin	King Saud Medical City	marketed	Polymyxin antibiotic	Bacterial lipopolysaccharides and phospholipids
High Dose Colistin	High Dose Colistin	King Saud Medical City	marketed	Polymyxin antibiotic	Bacterial lipopolysaccharide (LPS) and outer membrane
Colistin/Polymyxin B + Sulbactam	Colistin/Polymyxin B + Sulbactam	National University of Singapore	marketed	Polymyxin antibiotic + β-lactamase inhibitor combination	Bacterial cell membrane (polymyxins); bacterial β-lactamases (sulbactam)
Ceftazidime-avibactam + Colistin/Polymyxin B	Ceftazidime-avibactam + Colistin/Polymyxin B	National University of Singapore	marketed	Beta-lactam/beta-lactamase inhibitor + polymyxin antibiotic combination	Bacterial peptidoglycan cross-linking enzymes (PBPs); beta-lactamases; bacterial cell membrane lipopolysaccharide and phospholipids
polymixin/bacitracin	polymixin/bacitracin	Vanderbilt University Medical Center	phase 3	Polymyxin antibiotic

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polymyxin antibiotic class)

1. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
2. King Saud Medical City · 2 drugs in this class
3. Hospitales Universitarios Virgen del Rocío · 1 drug in this class
4. Mahmoud I Mostafa · 1 drug in this class
5. Merck Sharp & Dohme LLC · 1 drug in this class
6. Vanderbilt University Medical Center · 1 drug in this class